nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—SLC6A3—Gilles de la Tourette syndrome	0.558	0.635	CbGaD
Paroxetine—HTR2A—Gilles de la Tourette syndrome	0.321	0.365	CbGaD
Paroxetine—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.00664	0.132	CbGeAlD
Paroxetine—HTR2A—autonomic nervous system—Gilles de la Tourette syndrome	0.00399	0.0792	CbGeAlD
Paroxetine—TACR1—nervous system—Gilles de la Tourette syndrome	0.00207	0.0411	CbGeAlD
Paroxetine—TACR1—central nervous system—Gilles de la Tourette syndrome	0.00199	0.0395	CbGeAlD
Paroxetine—CHRM4—nervous system—Gilles de la Tourette syndrome	0.00195	0.0386	CbGeAlD
Paroxetine—CHRM4—central nervous system—Gilles de la Tourette syndrome	0.00187	0.0372	CbGeAlD
Paroxetine—TACR1—brain—Gilles de la Tourette syndrome	0.00158	0.0314	CbGeAlD
Paroxetine—CHRM5—nervous system—Gilles de la Tourette syndrome	0.00152	0.0302	CbGeAlD
Paroxetine—CHRM4—brain—Gilles de la Tourette syndrome	0.00149	0.0295	CbGeAlD
Paroxetine—CHRM5—central nervous system—Gilles de la Tourette syndrome	0.00146	0.0291	CbGeAlD
Paroxetine—SLC6A3—midbrain—Gilles de la Tourette syndrome	0.00127	0.0251	CbGeAlD
Paroxetine—CHRM5—brain—Gilles de la Tourette syndrome	0.00116	0.0231	CbGeAlD
Paroxetine—SLC6A4—midbrain—Gilles de la Tourette syndrome	0.00116	0.023	CbGeAlD
Paroxetine—CHRM5—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00111	0.0157	CbGpPWpGaD
Paroxetine—CHRM5—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00108	0.0152	CbGpPWpGaD
Paroxetine—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00106	0.015	CbGpPWpGaD
Paroxetine—CHRM4—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00105	0.0148	CbGpPWpGaD
Paroxetine—CHRM2—nervous system—Gilles de la Tourette syndrome	0.00104	0.0207	CbGeAlD
Paroxetine—SLC6A3—nervous system—Gilles de la Tourette syndrome	0.00104	0.0207	CbGeAlD
Paroxetine—CHRM2—central nervous system—Gilles de la Tourette syndrome	0.00101	0.0199	CbGeAlD
Paroxetine—CHRM5—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.001	0.0142	CbGpPWpGaD
Paroxetine—SLC6A3—central nervous system—Gilles de la Tourette syndrome	0.001	0.0199	CbGeAlD
Paroxetine—CHRM4—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000974	0.0138	CbGpPWpGaD
Paroxetine—SLC6A4—nervous system—Gilles de la Tourette syndrome	0.000954	0.0189	CbGeAlD
Paroxetine—CHRM1—nervous system—Gilles de la Tourette syndrome	0.00095	0.0189	CbGeAlD
Paroxetine—CHRM4—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000945	0.0134	CbGpPWpGaD
Paroxetine—CHRM5—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000933	0.0132	CbGpPWpGaD
Paroxetine—HTR2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000921	0.013	CbGpPWpGaD
Paroxetine—SLC6A4—central nervous system—Gilles de la Tourette syndrome	0.000918	0.0182	CbGeAlD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000916	0.013	CbGpPWpGaD
Paroxetine—CHRM1—central nervous system—Gilles de la Tourette syndrome	0.000915	0.0182	CbGeAlD
Paroxetine—CHRM3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000913	0.0129	CbGpPWpGaD
Paroxetine—CHRM5—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000905	0.0128	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000904	0.0128	CbGpPWpGaD
Paroxetine—CHRM4—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000881	0.0125	CbGpPWpGaD
Paroxetine—CHRM3—nervous system—Gilles de la Tourette syndrome	0.00085	0.0169	CbGeAlD
Paroxetine—CHRM5—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000843	0.0119	CbGpPWpGaD
Paroxetine—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.00084	0.0167	CbGeAlD
Paroxetine—CHRM3—central nervous system—Gilles de la Tourette syndrome	0.000819	0.0162	CbGeAlD
Paroxetine—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.000809	0.016	CbGeAlD
Paroxetine—CHRM2—brain—Gilles de la Tourette syndrome	0.000798	0.0158	CbGeAlD
Paroxetine—SLC6A3—brain—Gilles de la Tourette syndrome	0.000796	0.0158	CbGeAlD
Paroxetine—HTR2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000785	0.0111	CbGpPWpGaD
Paroxetine—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000781	0.011	CbGpPWpGaD
Paroxetine—CHRM3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000779	0.011	CbGpPWpGaD
Paroxetine—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000771	0.0109	CbGpPWpGaD
Paroxetine—HTR2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000762	0.0108	CbGpPWpGaD
Paroxetine—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000758	0.0107	CbGpPWpGaD
Paroxetine—CHRM3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000756	0.0107	CbGpPWpGaD
Paroxetine—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000749	0.0106	CbGpPWpGaD
Paroxetine—CHRM4—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000734	0.0104	CbGpPWpGaD
Paroxetine—SLC6A4—brain—Gilles de la Tourette syndrome	0.000729	0.0145	CbGeAlD
Paroxetine—CHRM1—brain—Gilles de la Tourette syndrome	0.000726	0.0144	CbGeAlD
Paroxetine—HTR2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00071	0.01	CbGpPWpGaD
Paroxetine—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000707	0.00999	CbGpPWpGaD
Paroxetine—CHRM3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000704	0.00996	CbGpPWpGaD
Paroxetine—CHRM5—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000703	0.00994	CbGpPWpGaD
Paroxetine—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000697	0.00986	CbGpPWpGaD
Paroxetine—HTR2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00066	0.00934	CbGpPWpGaD
Paroxetine—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000657	0.00929	CbGpPWpGaD
Paroxetine—CHRM3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000655	0.00926	CbGpPWpGaD
Paroxetine—CHRM3—brain—Gilles de la Tourette syndrome	0.00065	0.0129	CbGeAlD
Paroxetine—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000648	0.00917	CbGpPWpGaD
Paroxetine—SLC6A2—brain—Gilles de la Tourette syndrome	0.000642	0.0127	CbGeAlD
Paroxetine—HTR2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000641	0.00906	CbGpPWpGaD
Paroxetine—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000638	0.00901	CbGpPWpGaD
Paroxetine—CHRM3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000635	0.00899	CbGpPWpGaD
Paroxetine—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000629	0.0089	CbGpPWpGaD
Paroxetine—CYP2B6—nervous system—Gilles de la Tourette syndrome	0.000619	0.0123	CbGeAlD
Paroxetine—CHRM4—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000617	0.00872	CbGpPWpGaD
Paroxetine—HTR2A—midbrain—Gilles de la Tourette syndrome	0.000614	0.0122	CbGeAlD
Paroxetine—HTR2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000597	0.00844	CbGpPWpGaD
Paroxetine—CYP2B6—central nervous system—Gilles de la Tourette syndrome	0.000596	0.0118	CbGeAlD
Paroxetine—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000594	0.0084	CbGpPWpGaD
Paroxetine—CHRM3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000592	0.00837	CbGpPWpGaD
Paroxetine—CHRM5—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000591	0.00835	CbGpPWpGaD
Paroxetine—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000586	0.00829	CbGpPWpGaD
Paroxetine—CYP2C8—brain—Gilles de la Tourette syndrome	0.000527	0.0105	CbGeAlD
Paroxetine—HTR2A—nervous system—Gilles de la Tourette syndrome	0.000505	0.01	CbGeAlD
Paroxetine—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000495	0.007	CbGpPWpGaD
Paroxetine—CHRM3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000493	0.00697	CbGpPWpGaD
Paroxetine—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000488	0.00691	CbGpPWpGaD
Paroxetine—HTR2A—central nervous system—Gilles de la Tourette syndrome	0.000486	0.00964	CbGeAlD
Paroxetine—CYP2B6—brain—Gilles de la Tourette syndrome	0.000473	0.00938	CbGeAlD
Paroxetine—TACR1—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000461	0.00652	CbGpPWpGaD
Paroxetine—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.00046	0.00912	CbGeAlD
Paroxetine—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.000443	0.00878	CbGeAlD
Paroxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000436	0.00616	CbGpPWpGaD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000417	0.0059	CbGpPWpGaD
Paroxetine—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000416	0.00588	CbGpPWpGaD
Paroxetine—CHRM3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000415	0.00586	CbGpPWpGaD
Paroxetine—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000411	0.00581	CbGpPWpGaD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000405	0.00573	CbGpPWpGaD
Paroxetine—ABCB1—midbrain—Gilles de la Tourette syndrome	0.000402	0.00798	CbGeAlD
Paroxetine—TACR1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000399	0.00564	CbGpPWpGaD
Paroxetine—HTR2A—brain—Gilles de la Tourette syndrome	0.000386	0.00765	CbGeAlD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000377	0.00533	CbGpPWpGaD
Paroxetine—SLC6A4—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000365	0.00517	CbGpPWpGaD
Paroxetine—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000357	0.00505	CbGpPWpGaD
Paroxetine—CYP2D6—brain—Gilles de la Tourette syndrome	0.000351	0.00697	CbGeAlD
Paroxetine—HTR2A—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.000349	0.00493	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.000346	0.00489	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.000343	0.00484	CbGpPWpGaD
Paroxetine—HTR2A—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.000339	0.00479	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.000336	0.00475	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.000333	0.0047	CbGpPWpGaD
Paroxetine—ABCB1—nervous system—Gilles de la Tourette syndrome	0.000331	0.00656	CbGeAlD
Paroxetine—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.000318	0.00632	CbGeAlD
Paroxetine—TACR1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000318	0.00449	CbGpPWpGaD
Paroxetine—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000314	0.00444	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000308	0.00436	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000307	0.00435	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000299	0.00422	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000287	0.00406	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000278	0.00393	CbGpPWpGaD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000264	0.00374	CbGpPWpGaD
Paroxetine—ABCB1—brain—Gilles de la Tourette syndrome	0.000253	0.00502	CbGeAlD
Paroxetine—CHRM4—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000241	0.00341	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000239	0.00337	CbGpPWpGaD
Paroxetine—CHRM4—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000234	0.00331	CbGpPWpGaD
Paroxetine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000224	0.00316	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.000219	0.0031	CbGpPWpGaD
Paroxetine—CHRM4—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000218	0.00308	CbGpPWpGaD
Paroxetine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000217	0.00307	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.000217	0.00307	CbGpPWpGaD
Paroxetine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000214	0.00303	CbGpPWpGaD
Paroxetine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000208	0.00294	CbGpPWpGaD
Paroxetine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000202	0.00286	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000201	0.00285	CbGpPWpGaD
Paroxetine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000198	0.0028	CbGpPWpGaD
Paroxetine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000194	0.00274	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000192	0.00271	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000186	0.00263	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000184	0.0026	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000183	0.00259	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00018	0.00254	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000179	0.00253	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000178	0.00252	CbGpPWpGaD
Paroxetine—CHRM5—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000175	0.00248	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000174	0.00246	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000173	0.00245	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000166	0.00235	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000166	0.00235	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000163	0.00231	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000162	0.0023	CbGpPWpGaD
Paroxetine—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00016	0.00227	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000158	0.00224	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000157	0.00222	CbGpPWpGaD
Paroxetine—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000156	0.0022	CbGpPWpGaD
Paroxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000152	0.00214	CbGpPWpGaD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000151	0.00213	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00015	0.00212	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000149	0.0021	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000147	0.00208	CbGpPWpGaD
Paroxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000147	0.00208	CbGpPWpGaD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000146	0.00207	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000146	0.00206	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000146	0.00206	CbGpPWpGaD
Paroxetine—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000145	0.00205	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000144	0.00204	CbGpPWpGaD
Paroxetine—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000142	0.002	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000142	0.002	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000141	0.00199	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00014	0.00198	CbGpPWpGaD
Paroxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000137	0.00194	CbGpPWpGaD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000136	0.00193	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000136	0.00192	CbGpPWpGaD
Paroxetine—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000136	0.00192	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000136	0.00192	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000135	0.0019	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000132	0.00187	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00013	0.00184	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000129	0.00183	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000129	0.00182	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000128	0.0018	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000126	0.00179	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000126	0.00178	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000125	0.00177	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000125	0.00177	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000124	0.00175	CbGpPWpGaD
Paroxetine—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000124	0.00175	CbGpPWpGaD
Paroxetine—CHRM3—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000123	0.00174	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000121	0.00172	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000117	0.00166	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000117	0.00165	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000116	0.00165	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000116	0.00164	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000115	0.00163	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000114	0.00161	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00011	0.00156	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00011	0.00156	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000103	0.00146	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000101	0.00142	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	9.89e-05	0.0014	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	9.84e-05	0.00139	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	9.8e-05	0.00139	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	9.71e-05	0.00137	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	9.63e-05	0.00136	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.6e-05	0.00136	CbGpPWpGaD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	9.55e-05	0.00135	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.55e-05	0.00135	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	9.52e-05	0.00135	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.52e-05	0.00135	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	9.43e-05	0.00133	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.43e-05	0.00133	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—HDC—Gilles de la Tourette syndrome	9.4e-05	0.00133	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	9.35e-05	0.00132	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	9.24e-05	0.00131	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	8.94e-05	0.00126	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	8.9e-05	0.00126	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	8.87e-05	0.00125	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	8.85e-05	0.00125	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	8.78e-05	0.00124	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	8.71e-05	0.00123	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	8.24e-05	0.00117	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	8.18e-05	0.00116	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	8.16e-05	0.00115	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—HDC—Gilles de la Tourette syndrome	8.09e-05	0.00114	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	8.08e-05	0.00114	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	8e-05	0.00113	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	7.89e-05	0.00112	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	7.66e-05	0.00108	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	7.49e-05	0.00106	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	7.46e-05	0.00105	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.27e-05	0.00103	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	7.17e-05	0.00101	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	7.14e-05	0.00101	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	6.96e-05	0.000984	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—HDC—Gilles de la Tourette syndrome	6.85e-05	0.000968	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	6.77e-05	0.000957	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	6.48e-05	0.000917	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.23e-05	0.000881	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.21e-05	0.000878	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.15e-05	0.00087	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	6.1e-05	0.000863	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	5.97e-05	0.000843	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	5.62e-05	0.000795	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.59e-05	0.00079	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—HDC—Gilles de la Tourette syndrome	5.57e-05	0.000788	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.56e-05	0.000786	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.54e-05	0.000783	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.49e-05	0.000776	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.43e-05	0.000767	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.4e-05	0.000763	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.38e-05	0.000761	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.33e-05	0.000753	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.22e-05	0.000738	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.07e-05	0.000718	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.05e-05	0.000715	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.05e-05	0.000714	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.03e-05	0.000711	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.03e-05	0.000711	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.01e-05	0.000709	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5e-05	0.000707	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	4.98e-05	0.000705	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	4.96e-05	0.000702	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.93e-05	0.000697	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.9e-05	0.000693	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.88e-05	0.000691	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	4.84e-05	0.000684	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.74e-05	0.00067	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.59e-05	0.000649	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.57e-05	0.000645	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.55e-05	0.000643	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.54e-05	0.000642	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.51e-05	0.000637	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	4.43e-05	0.000627	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.42e-05	0.000625	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.29e-05	0.000607	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.24e-05	0.000599	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.11e-05	0.000581	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4e-05	0.000565	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.83e-05	0.000542	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.52e-05	0.000498	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.51e-05	0.000496	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.48e-05	0.000491	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.2e-05	0.000452	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.19e-05	0.000451	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.16e-05	0.000446	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3e-05	0.000424	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.98e-05	0.000422	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.97e-05	0.00042	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.94e-05	0.000416	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.91e-05	0.000412	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.89e-05	0.000409	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.89e-05	0.000408	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.86e-05	0.000404	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.8e-05	0.000396	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.71e-05	0.000383	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.7e-05	0.000381	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.69e-05	0.00038	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.68e-05	0.000379	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.66e-05	0.000376	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.89e-05	0.000267	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.88e-05	0.000266	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.86e-05	0.000264	CbGpPWpGaD
